- Home
- WES vs BBIO Comparison
WES vs BBIO Comparison
Compare WES & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WES | BBIO |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | 14.2B |
| IPO Year | 2012 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WES | BBIO |
|---|---|---|
| Price | $41.65 | $69.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 25 |
| Target Price | $41.71 | ★ $86.04 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 9.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,843,403,000.00 | $502,076,000.00 |
| Revenue This Year | $6.42 | $89.45 |
| Revenue Next Year | $6.99 | $73.78 |
| P/E Ratio | $14.73 | ★ N/A |
| Revenue Growth | 6.61 | ★ 126.26 |
| 52 Week Low | $35.25 | $31.77 |
| 52 Week High | $44.74 | $84.94 |
Technical Indicators
Market Signals| Indicator | WES | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 56.34 | 40.40 |
| Support Level | $39.78 | $61.95 |
| Resistance Level | $42.80 | $78.96 |
| Average True Range (ATR) | 0.66 | 4.00 |
| MACD | 0.08 | -0.72 |
| Stochastic Oscillator | 86.00 | 2.54 |
Price Performance
Historical ComparisonAbout WES Western Midstream Partners LP
Western Midstream Partners LP is a USA-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma) and Texas.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.